BIX0 Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.90 |
| 52 Week High | SEK 4.30 |
| 52 Week Low | SEK 1.26 |
| Beta | 0.38 |
| 11 Month Change | 5.12% |
| 3 Month Change | 15.21% |
| 1 Year Change | 195.90% |
| 33 Year Change | -7.71% |
| 5 Year Change | 102.60% |
| Change since IPO | -76.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIX0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.5% | -0.7% | 0.2% |
| 1Y | 195.9% | -17.2% | 8.5% |
Return vs Industry: BIX0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: BIX0 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| BIX0 volatility | |
|---|---|
| BIX0 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: BIX0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BIX0's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 115 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206.
BioInvent International AB (publ) Fundamentals Summary
| BIX0 fundamental statistics | |
|---|---|
| Market cap | €254.92m |
| Earnings (TTM) | -€35.62m |
| Revenue (TTM) | €3.36m |
75.9x
P/S Ratio-7.2x
P/E RatioIs BIX0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIX0 income statement (TTM) | |
|---|---|
| Revenue | SEK 38.64m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 38.64m |
| Other Expenses | SEK 448.29m |
| Earnings | -SEK 409.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -6.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,060.29% |
| Debt/Equity Ratio | 0% |
How did BIX0 perform over the long term?
See historical performance and comparison